Braeburn

Braeburn products

BRIXADI®

• Generic: buprenorphine extended-release injection (subcutaneous)

• Indication: moderate to severe opioid use disorder (OUD) in patients already initiated on or transitioning from transmucosal buprenorphine

• Usage / Dosing: administered by healthcare providers; available in weekly and monthly dosing schedules via subcutaneous injection

Probuphine®

• Generic: buprenorphine implant

• Indication: maintenance treatment of opioid addiction (for clinically stable patients already on low-dose transmucosal buprenorphine)

• Usage / Dosing: healthcare provider inserts four small implants under the skin of the upper arm; designed to deliver consistent medication over six months

Investigational Pipeline Products

• CAM2038 – weekly and monthly subcutaneous injectable depot of buprenorphine (investigated for OUD and chronic pain)

• BB0417 – injectable combining buprenorphine with granisetron for acute pain

• BB0817 – six-month risperidone implant being studied for schizophrenia